Dai ichi Life Insurance Company Ltd Buys Shares of 9,299 Hologic, Inc. (NASDAQ:HOLX)

Dai ichi Life Insurance Company Ltd purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the third quarter, Holdings Channel.com reports. The firm purchased 9,299 shares of the medical equipment provider’s stock, valued at approximately $757,000.

Several other institutional investors have also made changes to their positions in HOLX. Innealta Capital LLC bought a new stake in Hologic during the second quarter worth approximately $25,000. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the 3rd quarter worth $25,000. iA Global Asset Management Inc. acquired a new position in Hologic in the 1st quarter valued at $37,000. Sunbelt Securities Inc. bought a new position in Hologic in the 2nd quarter worth $37,000. Finally, First Horizon Advisors Inc. grew its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Raymond James increased their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Royal Bank of Canada boosted their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Finally, Evercore ISI increased their target price on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Trading Up 0.6 %

HOLX stock opened at $79.44 on Friday. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The business’s 50 day moving average is $80.28 and its 200-day moving average is $78.42. The firm has a market cap of $18.45 billion, a P/E ratio of 23.86, a P/E/G ratio of 2.51 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the prior year, the business posted $0.89 earnings per share. The business’s revenue was up 4.5% compared to the same quarter last year. Equities analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.